Top

Published in:

Open Access 01-10-2014 | Original Research Article

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

Authors: Margreke J. E. Brill, Anne van Rongen, Aletta P. I. Houwink, Jacobus Burggraaf, Bert van Ramshorst, René J. Wiezer, Eric P. A. van Dongen, Catherijne A. J. Knibbe

Published in: Clinical Pharmacokinetics | Issue 10/2014

Abstract

Background

While in vitro and animal studies have shown reduced cytochrome P450 (CYP) 3A activity due to obesity, clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence both clearance and oral bioavailability in a distinct manner, in this study the pharmacokinetics of the CYP3A substrate midazolam were evaluated after semi-simultaneous oral and intravenous administration in morbidly obese patients, and compared with healthy volunteers.

Methods

Twenty morbidly obese patients [mean body weight 144 kg (range 112–186 kg) and mean body mass index 47 kg/m² (range 40–68 kg/m²)] participated in the study. All patients received a midazolam 7.5 mg oral and 5 mg intravenous dose (separated by 159 ± 67 min) and per patient 22 samples over 11 h were collected. Data from 12 healthy volunteers were available for a population pharmacokinetic analysis using NONMEM^®.

Results

In the three-compartment model in which oral absorption was characterized by a transit absorption model, population mean clearance (relative standard error %) was similar [0.36 (4 %) L/min], while oral bioavailability was 60 % (13 %) in morbidly obese patients versus 28 % (7 %) in healthy volunteers (P < 0.001). Central and peripheral volumes of distribution increased substantially with body weight (both P < 0.001) and absorption rate (transit rate constant) was lower in morbidly obese patients [0.057 (5 %) vs. 0.130 (14 %) min^–1, P < 0.001].

Conclusions

In morbidly obese patients, systemic clearance of midazolam is unchanged, while oral bioavailability is increased. Given the large increase in volumes of distribution, dose adaptations for intravenous midazolam should be considered. Further research should elucidate the exact physiological changes at intestinal and hepatic level contributing to these findings.

Available only for authorised users

Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889–91. doi:10.1038/ijo.2012.159.CrossRef

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of Obesity in the United Stated, 2009–2010. NCHS Data Brief 2012. http://www.cdc.gov/nchs/data/databriefs/db82.pdf. Accessed 11 Aug 2014.

World Obesity Federation. 2014. Registered in England and Wales, 3802726. http://www.worldobesity.org/aboutobesity/world-map-obesity/. Accessed 15 Aug 2014.

Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res. 2006;23(6):1188–200. doi:10.1007/s11095-006-0071-6.PubMedCrossRef

Ghose R, Omoluabi O, Gandhi A, Shah P, Strohacker K, Carpenter KC, et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 2011;89(1–2):57–64. doi:10.1016/j.lfs.2011.05.005.PubMedPubMedCentralCrossRef

Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37(10):2087–94. doi:10.1124/dmd.109.027466.PubMedPubMedCentralCrossRef

Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5(3):388–93. doi:10.1016/j.cgh.2006.12.021.PubMedCrossRef

Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver—the link between adipocytes and hepatocytes. Digestion. 2011;83(1–2):124–33. doi:10.1159/000318741.PubMedCrossRef

Moretto M, Kupski C, Mottin CC, Repetto G, Garcia Toneto M, Rizzolli J, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13(4):622–4.PubMedCrossRef

10.

Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41. doi:10.1016/j.pharmthera.2012.12.007.PubMedCrossRef

11.

Flockhart A. Cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/clinpharm/ddis/clinical-table/. Accessed 29 Apr 2014.

12.

Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93(3):275–82. doi:10.1038/clpt.2012.261.PubMedCrossRef

13.

Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37(1):8–19.PubMed

14.

Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304. doi:10.2165/11599410-000000000-00000.PubMedCrossRef

15.

Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27–35.PubMedCrossRef

16.

Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9. doi:10.1172/JCI25102.PubMedPubMedCentralCrossRef

17.

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–9. doi:10.1016/j.jaci.2005.02.023 quiz 20.PubMedCrossRef

18.

Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther. 2010;87(4):407–16. doi:10.1038/clpt.2009.311.PubMedCrossRef

19.

Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002;16(13):1799–801. doi:10.1096/fj.02-0195fje.PubMed

20.

Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123–49. doi:10.1146/annurev.pharmtox.46.120604.141059.PubMedCrossRef

21.

Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab. 2004;5(3):235–43.PubMedCrossRef

22.

Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res. 2006;12(24):7492–7. doi:10.1158/1078-0432.CCR-06-0023.PubMedCrossRef

23.

Yang J, Hao C, Yang D, Shi D, Song X, Luan X, et al. Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. Toxicol Lett. 2010;197(3):219–26. doi:10.1016/j.toxlet.2010.06.003.PubMedPubMedCentralCrossRef

24.

Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of critical illness and inflammation on midazolam therapy in children. Pediatr Crit Care Med. 2010. doi:10.1097/PCC.0b013e3181fe406d.

25.

Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia. 1987;42(6):619–26.PubMedCrossRef

26.

Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10(3):187–216.PubMedCrossRef

27.

Lindell M, Karlsson MO, Lennernas H, Pahlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest. 2003;33(6):493–9.PubMedCrossRef

28.

Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005;60(1):54–60. doi:10.1111/j.1365-2125.2005.02389.x.PubMedPubMedCentralCrossRef

29.

Beal S, Sheiner LB, Boeckmann A. NONMEM user’s guides (1989–2006). Ellicott City: Icon Development Solutions; 2006.

30.

Brendel K, Comets E, Laffont CM, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036–49.PubMedPubMedCentralCrossRef

31.

Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711–26. doi:10.1007/s10928-007-9066-0.PubMedCrossRef

32.

Bonate P. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer; 2006.

33.

Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.PubMedCrossRef

34.

Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16(6):697–701. doi:10.1381/096089206777346682.PubMedCrossRef

35.

Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984;9(2):177–83.PubMedCrossRef

36.

Li XS, Nielsen J, Cirincione B, Li H, Addy C, Wagner J, et al. Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J. 2010;12(4):537–47. doi:10.1208/s12248-010-9212-2.PubMedPubMedCentralCrossRef

37.

Caraco Y, Zylber-Katz E, Berry EM, Levy M. Significant weight reduction in obese subjects enhances carbamazepine elimination. Clin Pharmacol Ther. 1992;51(5):501–6.PubMedCrossRef

38.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 2007;8(7):676–84.PubMedCrossRef

39.

Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology. 2002;35(6):1549–50. doi:10.1053/jhep.2002.33215; author reply 50–1.PubMedCrossRef

40.

Teixeira TF, Souza NC, Chiarello PG, Franceschini SC, Bressan J, Ferreira CL, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31(5):735–40. doi:10.1016/j.clnu.2012.02.009.PubMedCrossRef

41.

Horton F, Wright J, Smith L, Hinton PJ, Robertson MD. Increased intestinal permeability to oral chromium (Cr)—EDTA in human Type 2 diabetes. Diabet Med. 2013. doi:10.1111/dme.12360.

42.

Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225–37. doi:10.1208/s12248-009-9099-y.PubMedPubMedCentralCrossRef

43.

Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol. 1981;19(4):271–8.PubMedCrossRef

44.

Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39–44.

45.

Messerli FH, Sundgaard-Riise K, Reisin E, Dreslinski G, Dunn FG, Frohlich E. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med. 1983;74(5):808–12.PubMedCrossRef

46.

Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23(8–9):369–76.PubMedCrossRef

47.

Karlsson MO, Bredberg U. Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharm Res. 1989;6(9):817–21.PubMedCrossRef

48.

Karlsson MO, Bredberg U. Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study. J Pharmacokinet Biopharm. 1990;18(2):103–20.PubMedCrossRef

49.

Bredberg U, Karlsson MO, Borgstrom L. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther. 1992;52(3):239–48.PubMedCrossRef

50.

Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72(6):718–28. doi:10.1067/mcp.2002.129068.PubMedCrossRef

Title: Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
Authors: Margreke J. E. Brill
Anne van Rongen
Aletta P. I. Houwink
Jacobus Burggraaf
Bert van Ramshorst
René J. Wiezer
Eric P. A. van Dongen
Catherijne A. J. Knibbe
Publication date: 01-10-2014
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 10/2014
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-014-0166-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2014

Erratum to: Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition

Review of Evidence for Measuring Drug Concentrations of First-Line Antitubercular Agents in Adults

Pharmacokinetic Enhancers in HIV Therapeutics

Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1–11 Years

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

Effect of a Roux-en-Y Gastric Bypass on the Pharmacokinetics of Oral Morphine Using a Population Approach